Insilico Medicine Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:2014
Lead Investor(s):N/A

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Insilico Medicine's estimated annual revenue is currently $10.9M per year.
  • Insilico Medicine's estimated revenue per employee is $155,000

Employee Data

  • Insilico Medicine has 70 Employees.
  • Insilico Medicine grew their employee count by 25% last year.
  • Insilico Medicine currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Intralytix
$4.7M30N/AN/AN/A
OriGene Technol...
$15.7M101-4%N/AN/A
American Gene T...
$4.7M30N/AN/AN/A
Profectus Biosc...
$3.9M25N/AN/AN/A
BioIT Solutions
$1.9M12N/AN/AN/A
BioReliance Cor...
$126.3M815N/AN/AN/A
Aziyo Biologics
$25.4M1644%N/AN/A
Osiris Therapeu...
N/A334N/AN/AN/A
Northwest Bioth...
N/A16N/AN/AN/A
Stemgent
$2.5M16N/AN/AN/A
Missing a competitor? Contribute!?
Submit

A company dedicated to finding novel solutions for aging and age-related diseases using advances in genomics and big data analysis. Description Our mission statement and our pledge to our investors, friends and families: Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself. This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility. Our goals are: to become the first and the largest drug discovery company in aging and age-related diseases; to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment; Some of our recent publications: Zhavoronkov A, Buzdin AA, Garazha AV, Borissov NM and Moskalev AA (2014) Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49. doi: 10.3389/fgene.2014.00049 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/full#sthash.6HfgzBx9.dpuf Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY and Borisov NM (2014). OncoFinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front. Genet. 5:55. doi: 10.3389/fgene.2014.00055 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00055/full#sthash.9XPxTZ3z.dpuf

keywords:N/A

70

Number of Employees

$10.9M

Revenue (est)

1

Current Jobs

25%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Insilico Medicine News

9-Sep-19 - Insilico Medicine Secures $37M in Series B Funding Led by ...

HONG KONG, Sept. 10, 2019 /PRNewswire/ -- Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug ...

13-Sep-19 - Insilico Medicine Raises $37M in Series B Funding

Insilico Medicine, a Hong Kong-based developer of next-generation artificial intelligence technology for drug discovery, completed a $37m ...

4-Sep-19 - Insilico Medicine Brings GENTRL AI System to Open Source ...

Insilico Medicine has developed GENTRL, a new artificial intelligence system for drug discovery that dramatically accelerates the process from ...